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Background: Helicobacter pylori is an important pathogen responsible for human gastric problems like
inflammation, ulcers and cancer. It is widely prevalent in developing countries with low socioeconomic status. Since
the infection remains asymptomatic in most individuals, efforts for efficient diagnostic markers to identify high risk
patients are warranted. In this study, we constructed an expression vector that overexpresses the H. pylori AhpC
protein as a glutathione S-transferase fusion protein. We furthermore examined whether this recombinant fusion
protein retained immunogenicity and thus would be useful as a diagnostic marker.
Findings: The full-length tsaA gene from H. pylori strain G27, which encodes AhpC, was cloned in plasmid vector
pGEX-6P-2 to create the recombinant plasmid vector pGEX-tsaA. The nucleotide sequence of the clone showed
100% homology with corresponding published sequence of original gene. Over-expression of the target protein
GST-AhpC was achieved in E. coli BL21 (DE3) cells by induction with isopropyl-beta-D-thiogalactoside (IPTG).
GST-AhpC was extracted and identified using SDS-PAGE as a 52 kDa protein. Western blotting results using
commercial antibodies against whole cell H. pylori showed that the fusion protein retained immunogenecity.
Conclusion: A recombinant prokaryotic expression system was successfully established with high expression
efficiency for target fusion gene pGEX-tsaA. The expressed GST-AhpC protein showed immunoreactivity against
commercial anti-H. pylori antibodies. This recombinant fusion protein can be developed as a diagnostic marker for
screening patients with chronic H. pylori infections.
Keywords: Prokaryotic expression system, H. pylori, tsaA, Alkyl hydroperoxide reductase, Recombinant fusion
protein, AhpCFindings
Background
Helicobacter pylori has been recognized as a human gas-
tric pathogen able to colonize in the stomachs of around
half of the world’s population [1]. Most infected indivi-
duals remain asymptomatic, however, the infection may
cause acute and chronic gastritis or peptic ulceration,
besides being a risk factor for development of gastric
adenocarcinoma, mucosa-associated lymphoid tissue
(MALT) lymphoma and primary gastric non-Hodgkin’s
lymphoma [2-5].* Correspondence: khalidadc@yahoo.co.uk
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distribution, and reproduction in any mediumH. pylori infection is acquired in early childhood. Like
all developing countries, the prevalence of H. pylori in-
fection in Pakistan is very high in children. Results of
urea breath test in infants from suburbs of Karachi
revealed that 80% were positive for H. pylori [6]. H. pyl-
ori is able to colonize human stomach for life, if not era-
dicated. Persistent colonization requires H. pylori to
avoid damage from by-products of oxygen metabolism
and oxidative host responses. H. pylori has an impressive
array of antioxidant proteins. The bacterium protects it-
self against such oxidative damage by expressing
enzymes like superoxide dismutase SodB [7], catalase
KatA [8] and KatA-associated protein KapA [9]. The ac-
tivities of alkyl hydroperoxide reductase AhpC [10], thiol
peroxidases Bcp and Tpx [11] have also been reported
to protect H. pylori against organic peroxides. NADPH
quinone reductase MdaB [12] and the iron-bindingd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Mehmood and Hasan BMC Research Notes 2012, 5:328 Page 2 of 9
http://www.biomedcentral.com/1756-0500/5/328protein NapA [13] were also found involved in resistance
to oxygen stress.
H. pylori AhpC is a thioredoxin (Trx)-dependent
AhpC and a member of the 2-Cys peroxiredoxin family
(2-Cys Prxs). AhpC is one of the major proteins for anti-
oxidant defense in H. pylori and plays an important role
in gastric colonization by the microbe [10]. The tsaA
gene was originally annotated as HP1563 in H. pylori
26695 [14] and HP1471 in H. pylori J99 [15], however
Chalker et al. (2001) annotated the gene as ahpC, be-
cause this nomenclature is more usual for bacterial alkyl
hydroperoxide reductase enzymes [16]. AhpC has been
reported in many bacteria, like Escherichia coli and Sal-
monella typhimurium [17]. H. pylori AhpC was reported
much near to eukaryotic Prxs unlike reductases found in
many other bacterial species and indeed, could act like a
molecular chaperone similar to Prxs present in yeast
and human [18]. Recently, AhpC was found to be con-
sistently expressed in higher amounts in H. pylori strains
isolated from gastric cancer patients than in patients
presenting gastritis only [19]. The 26-kDa protein first
reported as an antigenically conserved H. pylori species
specific protein, is now being predicted to be a useful
diagnostic marker for detection of H. pylori infection
[20]. It was also found associated with a specific anti-
body response in patients with adenocarcinoma [21].
In the present study, a recombinant expression plas-
mid containing whole tsaA gene from H. pylori G27 was
constructed. The plasmid was cloned in E. coli BL21
cells and recombinant fusion protein was expressed,
extracted, identified and analyzed for immunoreactivity
with commercial anti H. pylori antibodies. The results of
this initial work provide a basis for future studies using
this fusion protein to develop a specific diagnostic mar-
ker for detection of advanced stage diseases like peptic
ulcer, gastric cancer and adenocarcinoma due to chronic
H. pylori infection in Pakistani population.
Results
Polymerase chain reaction, cloning and transformation
The full-length tsaA gene was amplified as described in
the methods, digested with restriction enzymes and
ligated with pGEX-6p-2 that had been cut with the same
enzymes to generate pGEX-tsaA. This plasmid places
the GST coding sequences N-terminal to the TsaA/AhpC
coding sequences and thus should generate rGST-AhpC
fusion protein (Figure 1). pGEX-tsaA was used to trans-
form E. coli DH10B to ampicillin resistance, and the cor-
rect nature of pGEX-tsaA was verified using PCR and
DNA sequencing (Figure 2).
Expression of target fusion protein
We next examined whether pGEX-tsaA would overex-
press rGST-AhpC. For this experiment we transformedpGEX-tsaA into the E. coli strain BL21 (DE3) that encodes
a chromosomal T7 RNA Polymerase under the control of
a tac promoter. Under IPTG induction, the tac promoter
gets activated that drives expression of the rGST-AhpC.
We thus added IPTG at concentrations of 0.1 and
1 mmol/L to mid-log phase cultures of pGEX-tsa- BL21
(DE3) grown at 37 °C, and collected whole cell proteins
for SDS-PAGE gel analysis. We found that pGEX-tsaA
expressed robust amounts of rGST-AhpC that migrated at
the expected size of 52 kDa (Figure 3). Further analysis
demonstrated that this rGST-AhpC was mainly present as
inclusion bodies, based on the observation that the protein
was not soluble after cell lysis (Data not shown).
Immunoreactivity of GST-AhpC
Although it is well known that antibodies against AhpC
are generated during H. pylori infection, we did not
know if such antiserum would recognize a rGST-AhpC
fusion protein. We thus tested whether a commercial
rabbit antibody that had been generated against whole
cell H. pylori would recognize our recombinant rGST-
AhpC. We obtained robust recognition, confirming that
this recombinant protein still displays critical antigenic
determinants (Figure 4).
Purification of fusion protein
Target fusion protein rGST-AhpC was extracted from
large volume LB-Amp culture (1 L) using repeat sonic-
ation and washing followed by centrifugation after each
step. The samples were checked on 10-12% SDS-PAGE
gel for protein quality. Pellet after third sonication and
centrifugation step (Pellet-III) showed best results with a
good intense band and little degradation/cleavage pro-
ducts. Pellet-III sample was dialyzed and the super-
natant, after dialysis was concentrated to approx. 3 ml.
Right sized band for fusion protein was observed in case
of both dialyzed and concentrated protein samples with
no apparent degradation product as compared to pellet-
III sample without dialysis and concentration (Figure 5).
Discussion
The study of virulence factors and important antigens of
H. pylori is important to understand bacterial mechan-
isms involved in persistent colonization and inflamma-
tion. Prokaryotic expression systems for several
important H. pylori virulence factors have been success-
fully constructed and recombinant fusion proteins or
their purified proteins used in seroprevalence studies or
screened as H. pylori vaccine candidates [22-24], how-
ever, little attention has been paid towards protein pro-
ducts of housekeeping genes like tsaA (ahpC).
Wang et al. (2005) reported that mutant H. pylori
strains defective in AhpC were more sensitive to oxidative
stress conditions compared to wild-type cells [25]. Also,
Figure 1 Schematic diagram of cloning and transformation of tsaA gene. Whole tsaA gene having BamH1 and EcoR1 sites was ligated with
pGEX-6p-2 that had been cut with the same enzymes to generate pGEX-tsaA. This plasmid was used to transform E. coli, which produces rGST-
AhpC fusion protein under induction with IPTG.
Mehmood and Hasan BMC Research Notes 2012, 5:328 Page 3 of 9
http://www.biomedcentral.com/1756-0500/5/328Olczak et al., (2003) reported that ahpC/tsaA mutant
strains were unable to colonize mouse stomach [26]. An
important feature of AhpC is that it seems to promote the
activity of other proteins. Specifically, loss of AhpC
resulted in partial inactivation of catalase, suggesting that
AhpC is required for proper catalase activity [27].
At least two studies reported that antibodies against
AhpC were found only in H. pylori infections that
resulted in disease. Wang et al., 2004 found antibodies
against AhpC in sera of peptic ulcer, cancer andadenocarcinoma patients infected with H. pylori [21]. In
a recent report, Haung et al., 2011 examined protein ex-
pression levels of AhpC in H. pylori from different clin-
ical manifestations and observed 5-fold increase in
AhpC protein expression in strains isolated from gastric
cancer patients than those from gastritis [19]. This
describes the potential of AhpC as an efficient biomarker
to identify and risk patient population presenting differ-
ent stages of dseases associated with chronic H. pylori
infections.
Figure 2 A. Target amplification fragments of tsaA gene. Lane 1: Low mass ladder (New England Biolab); Lanes 2 & 3: Target amplification
fragments of tsaA gene (~600 bp) form G27 and positive control 26695; Lane 4: Blank control. B. PCR showing E. coli BL21 colonies after cloning,
positive for tsaA gene by direct colony PCR method. Lane 1 is low mass ladder. Lanes with + sign show successful transformants. C. PCR for tsaA
using plasmid extracts of transformed E. coli BL21 colonies. Lane 1 is low mass ladder. Lanes with bands at target site (~600 bp) show successful
transformants.
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disease is CagA. Patients infected with cagA+ H. pylori
have higher risk of developing gastric cancers than those
infected with cagA- strains [28,29]. Various studies have
reported that 60 to 70% of H. pylori strains isolated from
European and North American populations carried the
cagA gene [30-32], whereas over 90% of the isolates from
Asia-Pacific populations were found to be cagA+ [33-35].
The fact that nearly all strains of H. pylori from coun-
tries like Taiwan and China as well as a high proportion
in western countries are cagA positive makes it difficult
to use cagA only as a marker for screening high-risk
patients in these populations.The tsaA gene from H pylori strain G27, cloned in this
study, showed 100% nucleotide homology with published
corresponding sequences. In the present study, SDS-
PAGE demonstrated that the constructed expression sys-
tems pGEX-6p-2-tsaA-BL21(DE3) efficiently produced
the target recombinant GST fusion protein, however
mainly presented in the form of inclusion body. How-
ever, we successfully obtained free of inclusion body fu-
sion protein using repeat sonication and centrifugation
protocol which can be extended to subsequent refolding
and cleavage from GST tag. The commercial rabbit anti-
serum against the whole cell of H. pylori recognized and
combined with rGST-AhpC as confirmed by Western
Figure 3 A. Growth curves showing OD600 of E. coli BL21 cells for induction of AhpC with 0.1 and 1 mM IPTG at 0, 2 and 4 hours of
growth. 1A and 2A are duplicate samples. B. SDS-PAGE showing ~52 kDa target recombinant fusion protein (rGST-AhpC). Lane 1: Kaleidoscope
colour marker (BioRad); Lanes 2–4 Protein samples induced with 0.1 mM IPTG at 0, 2 and 4 hours respectively; Lanes 6–7: Protein samples
induced with 1 mM IPTG; Lanes 5 & 8: Blank controls.
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noreactivity. However, we could not explain presence of
lower intensity bands other than that of the right sized
band, both in SDS-PAGE (Figure 3B) and their subse-
quent recognition in Western Blot (Figure 4). Perhaps
these are E. coli BL21 (DE3) proteins which cross-
reacted with the commercial rabbit antiserum against
the whole cell of H. pylori. Several other approaches
have been used for construction and use of prokaryotic
expression system for potential H. pylori vaccine
candidates like flaA, flab, ureB and cagA by other groups
[22-24].Limitations of present study include use of GST fusion
protein itself and not its cleaved purified product, and
not testing the sera of potential patient groups to dem-
onstrate the effectiveness of this approach due to some
constraints.
Conclusions
We have successfully constructed an efficient expression
system for ahpC, an important gene of H. pylori in
pGEX-6p-2. This construct was successfully transformed
in E. coli BL21 (DE3) that gave a recombinant fusion
protein (rGST-AhpC), mainly as inclusion body.
Figure 4 Western Blot showing detection of target ~52 kDa GST fusion protein by Rabbit anti H. pylori antibodies as primary antibody.
Lane 1: Kaleidoscope colour marker; Lanes 2–4: Protein samples induced in E. coli BL21 cells with 0.1 mM IPTG at 0, 2 and 4 hours respectively;
Lanes 6–7: Protein samples induced with 1 mM IPTG; Lanes 5 & 8: Blank controls.
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commercial anti-H. pylori antibodies raised in rabbit
serum. The fusion protein was then processed to get free
from inclusion body. This recombinant fusion protein
can serve as a potential diagnostic marker for screening
advanced clinical manifestations due to chronic H. pylori
infections. Such strategies are need of the time to iden-
tify high risk patients keeping in view the genetic diver-
sity of H. pylori regarding a well accepted biomarker
CagA across the globe.Figure 5 SDS-PAGE showing different purification steps for
fusion protein from pellet after sonication step III (P-III). Lane M:
Kaleidoscope colour marker; Lane 1: Dialyzed pellet before
lyophilization; Lane 2: Pellet-III after lyophilization; Lane 3: Pellet-III
before lyophilization: Lane 4: Dialyzed pellet after lyophilization; Lane
5: Dialyzed supernatant before lyophilization; Lane 6: Filtrate after
concentration and Lane 7: Concentrated fusion protein.Methods
Bacterial strains
Bacterial strains used are given in Table 1. E. coli strain
DH10B was used for cloning and BL21 (DE3) used for
protein expression.Growth media and chemicals
For solid-medium culture, H. pylori was grown on
Columbia blood agar (Becton Dickinson) plates with 5%
defibrinated horse blood (Hemostat Labs, Davis, CA),
5 μg of trimethoprim/ml, 8 μg of amphotericin B/ml,
10 μg of vancomycin/ml, 50 μg of cycloheximide/ml,
5 μg of cefsulodin/ml, 2.5 U of polymyxin B/ml, 0.2%
(wt/vol) β-cyclodextrin (Sigma) (CHBA) at 37°C under
conditions of 10% O2, 10% CO2 and 80%N2. All anti-
biotics were from Sigma or ISC Bioexpress. E. coli
strains were grown on LB Agar or broth with Ampicillin
and incubated on 37°C for overnight (LB-Amp). For
long-term storage of H. pylori strains, 3–5 day growth of
H. pylori was transferred to brucella broth having 10%
FBS (BB10), 1% β-cyclodextrin, 5% dimethyl sulfoxide
and 25% glycerol. The cells were frozen at −70°C after
pipetting and vortexing.DNA extraction
Genomic DNA from 2–3 days culture of H. pylori strain
G27 was extracted using Wizard genomic kit (Promega)
according to manufacturer’s instructions.
Table 1 Strains and plasmid used in the study
Strain Genotype/description Source
E. coli
DH10B Cloning strain Promega
BL21 (DE3) E. coli B F– dcm ompT hsdS (rB–mB–) gal λ(DE3) [pLysS Camr] Promega
H. pylori
G27 Wild type Nina R. Salama, University of Washington, Seattle, WA
26695 Wild type Karen M. Ottemann, UC Santa Cruz, CA
Plasmids
pGEX-6p-2 GST fusion plasmid Novagen
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Primers were designed from genome sequence of H. pyl-
ori 26695 (HP1563) to amplify the full-length sequence
of HP1563/tsaA using the U.C. Santa Cruz archeal gen-
ome browser (http://archaea.ucsc.edu). Forward primer
5′-CTCTGGATCCATGTTAGTTACAAAACTTGCC-3′
having restriction endonuclease site of BamH1 and re-
verse primer 5′-CTCTGAATTCTTAAAGCTTAATG-
GAATTTTC-3′ with EcoR1 site were used to amplify
full length tsaA gene from H. pylori G27 genomic DNA.
Primers were synthesized by Eurofins MWG Operon,
(Huntsville, USA).Polymerase chain reaction
PCR reaction mixture contained 100 ng of H. pylori G27
genomic DNA, 2.5 μl of dNTPs, 2.5 μl of 30 mM MgCl2
PCR buffer, 200 ng of each primer and 1 μl of Taq poly-
merase. Final volume was made to 25 μl with sterile
water. Genomic DNA of H. pylori 26695 in same con-
centration was used as positive control. PCR conditions
were: Initial melting at 94°C for 3 minutes, then 30
cycles of repeat melting at 94°C for 40 sec, annealing at
52°C for 40 seconds and initial extension at 72°C for 30
seconds, then final extension at 72°C for 3 minutes and
storage at 4°C until run on the gel. The results of PCR
were observed under UV light after electrophoresis on
1.5% agarose gel stained with ethidium bromide. The
expected size of tsaA amplification fragment was
~600 bp.Sequencing
Sequencing of PCR products was done by the DNA se-
quencing facility, UC Berkeley, CA. A sample containing
100 ng gel purified DNA and 0.8 pg of forward or re-
verse primer was adjusted to a total volume of ~13 μl in
dH2O. Sequences obtained were subjected to nucleotide
BLAST feature of National Center for Biotechnology In-
formation (NCBI) website (http://blast.ncbi.nlm.nih.gov/
Blast.cgi) for homology analyses with published tsaA
sequence of G27.Cloning of tsaA gene into plasmid vector
Gel purified tsaA whole gene was cloned into plasmid
vector pGEX-6p-2. Both the tsaA PCR product and plas-
mid were digested with restriction endonucleases
BamHI and EcoRI (New England Biolabs) at 37°C over-
night. Digested DNA and plasmid were gel purified and
concentration was determined by Nanodrop. The plas-
mid sample was treated with Shrimp alkaline phosphat-
ase (New England BioLabs). Ligation was done with 0.5
μl T4 ligase enzyme (New England Biolabs) by incubat-
ing the ligation mix at 16°C for overnight. This plasmid
was transformed into E. coli DH10B using electropor-
ation; ampicillin-resistant colonies were screened using
direct colony PCR using the original tsaA primers. One
colony containing the correct plasmid was used to purify
plasmid for sequencing.
Expression and identification of target recombinant
protein
pGEX-Recombinant plasmid was transformed through
electroporation into E. coli BL21 (DE3) (Promega). One
BL21 (DE3) colony of successful transformant contain-
ing pGEX-tsaA was cultured in LB-Amp broth at 37°C
until OD600 of 0.5, after which IPTG was added at con-
centrations of 0.1 and 1.0 and mmol/L. Cultures were
incubated for the times indicated in Figure 3A. Cells
were then collected by centrifugation at 6000 X g force.
The bacterial pellet was resuspended in 200–300 μl of
2x Laemmli sample buffer (1.52 g Tris-Base, 2 g SDS,
20 ml 100% glycerol, 2 ml β-merceptoethanol and 1 mg
bromophenol blue in dH2O to make 100 ml), and re-
suspended pellets were boiled for 5 minutes on water
bath for denaturing proteins. SDS-PAGE (10%) was used
to measure the molecular mass and output of the target
recombinant fusion protein (rGST-AhpC).
Immunoreactivity of recombinant fusion protein
Immunoreactivity of the fusion protein was then deter-
mined. Briefly, PVDF membrane (BioRad) cut to the size
of the gel was pre-wet in 100% Methanol. Gel, sponge
pads, 4 pieces of Whatman filter paper and MeOH-
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SDS-PAGE Running Buffer, 20% MeOH) for 10 minutes.
The cassettes were closed and placed in the module and
contents of the gel transferred to membrane at 250 mA
for 75 minutes. The commercial rabbit antiserum against
whole-cell H pylori (Santa Cruz Biotech. USA) in 1:1000
dilution and HRP-labeling sheep antiserum against
rabbit IgG in 1:7500 dilution (Santa Cruz Biotech, USA)
were used as the first and second antibodies to deter-
mine the immunoreactivity of rGST-AhpC by Western
blotting, respectively. Results were visualized using lumi-
nol and Biomax Light Film (Kodak).Isolation of fusion protein from inclusion bodies
The fusion protein was isolated from inclusion bodies by
using an online protocol (http://www.its.caltech.edu/
~bjorker/Protocols) with some modifications. Briefly,
culture from single colony of successful transformant
grown in 1 L LB-Amp broth was centrifuged (Sorvall
RC5C Plus, Thermo Fischer Scientific, Rockford, USA)
at 7000 X g for 20 minutes at 4°C. Resultant supernatant
was carefully decanted and pellet was resuspended in
13 ml of solution buffer (50 mM Tris–HCl, 25% sucrose,
1 mM NaEDTA, 0.1% Sodium azide and 10 mM DTT)
on ice and sonicated (Sonic Dismembrator, Fischer Sci-
entific, Rockford, USA) at 50% amplitude for 4–5 times
on ice. Then 100 μl Lysozyme, 250 μl DNase I and 50 μl
MgCl2 were mixed with 12.5 ml of lysis buffer (50 mM
Tris- HCl, 1% Triton X-100, 1% Na deoxycholate,
100 mM NaCl, 0.1% Sodium azide and 10 mM DTT)
and sample was incubated for 45 minutes at room
temperature. In next step, 350 μl of NaEDTA was added
to the sample and freezed in liquid nitrogen. The sample
was then thawed at 37°C for 30 minutes. 200 μl MgCl2
solution was added to the solution and placed at room
temperature for an hour. Then 350 ml NaEDTA was
added again to the solution and placed on ice. This solu-
tion was centrifuged at 11000 X g at 4°C for 20 minutes
and supernatant was discarded in a tube. The pellet was
washed with 10 ml washing buffer (50 mM Tris–HCl,
0.5% Triton X-100, 100 mM NaCl, 1 mM NaEDTA,
0.1% Sodium azide and 1 mM DTT) and sonicated on
ice. Solution was spun again at 11000 X g for 20 minutes
at 4°C and supernatant was discarded in a tube. Pellet
was again resuspended in 10 ml washing buffer but this
time without Triton X-100 and sonicated. The same
procedure was repeated for third time. Samples from
both supernatant and pellet after each centrifugation
step were retained for checking protein quality. In the
last step, pellet was dissolved in 5 ml of 8 M Guanidi-
nium solution (pH 8.0) in the presence of 4 mM DTT
and shaken at room temperature till complete dissol-
ution. The dissolved sample was stored at −80°C.Dialysis and concentration
Solution was diluted to 50 ml with minimal protein buf-
fer (150 mM NaCl and 50 mM Tris–HCl at pH 8.0) and
dialyzed against 1 L of MPB using SnakeSkin dialysis
tubing (Thermo Fischer Scientific, Rockford, USA) with
gentle shaking at 4 °C. After 2 hours of shaking, the buf-
fer was changed and then dialyzed overnight. Solution
was pelleted at 3000 X g for 20 minutes at 4 °C. The re-
sultant supernatant was concentrated to about 3 ml vol-
ume using Amicon Ultra-15 concentrator (Millipore,
USA) following manufacturer’s instructions. Both con-
centrated and dialyzed pellets were analyzed for proteins
on SDS-PAGE. Both the pellet and concentrate were lyo-
philized (FreeZone 2.5 Freeze Dry Systems, Labconco,
Kansas, USA) for long term storage and further use.
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